H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $48
Leerink Partners Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $40
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Prothena (PRTA) and CVS Health (CVS)
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Chardan Capital Initiates Coverage On Prothena Corp With Buy Rating, Announces Price Target of $40
Prothena Stock Soars Despite Study Miss